Pharmacelera, a CataloniaBio & HealthTech member, has signed a strategic agreement with the Cambridge Crystallographic Data Centre (CCDC) to share expertise on virtual screening and machine learning in order to help the centre’s scientists accelerate discovery of new drugs.
The CCDC is a renowned British drug discovery centre and Pharmacelera will contribute innovation, with latest-generation software like PharmScreen® (3D).
Recently, Pharmacelera has also announced research into new Parkinson drugs with the Autonomous University of Barcelona (UAB).
Photo: The Pharmacelera team at the company's offices in Barcelona - © Pharmacelera.
We recommend this video of CataloniaBioHT interviewing them:
Comments